Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | LDHA | P00338 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8515869 | 0.79 | GLA (0.37) | ALDH1A1MAPTFKBP1ASMN1; SMN2MEN1 | |
| SCHEMBL9882477 | 0.79 | CYP2D6 (0.40) | ALDH1A1MAPTPOLBFKBP1ASMN1; SMN2 | |
| SCHEMBL2200899 | 0.68 | ALDH1A1 (0.50) | ALDH1A1HTTPOLBL3MBTL1SMN1; SMN2 | |
| SCHEMBL8515475 | 0.67 | GLA (0.40) | ALDH1A1HTTMAPTL3MBTL1FKBP1A | |
| SCHEMBL874467 | 0.67 | CA1 (0.44) | HTTFKBP1ALDHAKMT2A | |
| SCHEMBL6626906 | 0.65 | ALDH1A1 (0.48) | ALDH1A1HTTMAPTPOLBSMN1; SMN2 | |
| SCHEMBL29002709 | 0.65 | GLA (0.44) | ALDH1A1KDM4EMAPTSMN1; SMN2 | |
| SCHEMBL28125189 | 0.65 | ALDH1A1 (0.39) | ALDH1A1KDM4EHTTMAPTL3MBTL1 | |
| SCHEMBL6627416 | 0.64 | ITGB1 (0.47) | ALDH1A1MAPTPOLBSMN1; SMN2LDHA | |
| SCHEMBL8355738 | 0.64 | ALDH1A1 (0.47) | ALDH1A1HTTPOLBL3MBTL1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120157448-A1 | COMPOUNDS FOR TREATING NEURODEGENERATIVE DISEASES | GENENTECH, INC. | 2012-06-21 | — | — | US | disclosed |
| US-20120157448-A1 | COMPOUNDS FOR TREATING NEURODEGENERATIVE DISEASES | GENENTECH, INC. | 2012-06-21 | — | — | US | disclosed |
| US-20120157448-A1 | COMPOUNDS FOR TREATING NEURODEGENERATIVE DISEASES | GENENTECH, INC. | 2012-06-21 | — | — | US | disclosed |
| WO-2012071458-A1 | HETEROCYCLIC INHIBITORS OF BETA - SECRETASE FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | ARRAY BIOPHARMA INC. (US) | 2012-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157448-A1 | COMPOUNDS FOR TREATING NEURODEGENERATIVE DISEASES | BACE1, PSEN1, PSEN2 | ALDH1A1 2346/4885KDM4E 3940/4885HTT 30/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.